Next-Generation Sequencing Market - Factors Driving Growth Post 2025

 Market Highlights

There are various diseases that have their roots in genetics such as cancer, diabetes, Alzheimer’s, arthritis, heart disease, etc. To discover viable treatment for these diseases, researchers are looking to discern how genes work. The next-generation sequencing market has been gaining impetus due to the fact that next-generation sequencing is integral to the field of genomics. The NGS technologies are implemented for several applications, including whole-genome sequencing, de novo assembly sequencing, resequencing, and transcriptome sequencing at the DNA or RNA level. The successful application of next-generation sequencing can lead to predicting genes, protein-coding regions, and pathways.

Illumina, Helicos Biosciences, Thermo Fisher Scientific, Roche, Pacific Bioscience, ABI Life Technologies, and Oxford Nanopore are some of the companies that are implementing different NGS technologies which in turn will augment global next-generation sequencing market which is estimated to reach at a CAGR of 18.05% over the forecast period and USD 20,347.45 Million by 2025.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6354 

Segmentation

The Next Generation Sequencing Market has been classified by Technology, Service and Product, Application, and End-User.

By technology, the next-generation sequencing market has been segmented as whole-genome sequencing, methyl sequencing, whole-exome sequencing, targeted resequencing, CHIP sequencing, RNA sequencing, and de novo sequencing.

By service & product, the next-generation sequencing market has been segmented as consumables, sample preparation, sequencing services, and platforms and services for platforms.

By application, the NGS market has been segmented as genetic screening, drug discovery, diagnostics, agriculture and animal research, and others.

End-users segmentation of the next generation sequencing market includes academic institutes and research centers, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users.

Regional Analysis

Owing to the rising number of funds being granted for research into genomics and initiatives adopted by the government to rein in cases of genetically occurring diseases and demand to improve the healthcare sector is estimated to augment the growth of the next-generation sequencing market in North America. Increased competition among market players as well as acquisitions and mergers are expected to drive the growth of the market in the region.

The next-generation sequencing market in Europe is expected to hold the second-largest revenue share due to the presence of some of the leading next-generation sequencing technology companies and an educated population inclined on the advancement of next-generation sequencing technology. Though diverse regulations and a fragmented NGS market might restrain the growth of the market in the region, favorable funding scenario and immense support for scientific research would augment the next-generation sequencing market in the region.

The next-generation sequencing market share in Asia-Pacific is projected to witness expansion over the coming years due to growing demand for advanced technology and access to enhanced treatment facilities, better adoption of advanced genomics, an increase in disposable income, and rising investments in diverse treatment options by pharmaceutical companies.

Due to lack of technical knowledge, an underdeveloped healthcare sector, and poor medical facilities the next-generation sequencing market in the Middle East and Africa is expected to garner the smallest share.

Competitive Landscape

Some of the Key Players in the Global Next-Generation Sequencing Market Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., BGI, PerkinElmer, Agilent Technologies, QIAGEN N. V., Macrogen Inc., Oxford Nanopore Technologies, Ltd., and Eurofins Scientific.

Industry News

Recently, Thermo Fisher Scientific launched its Ion Torrent Genexus System, the first fully integrated, next-generation sequencing platform that delivers results economically in a single day. This turnkey solution is designed to enable local hospitals to adopt NGS testing.

According to a study published in Clinical Lung Cancer local hospitals are severely challenged when it comes to providing NGS-based genomic testing at present even though hospitals are where most patients are treated. Due to limitations to NGS adoption, such as product complexity and cost, the vast majority of local molecular laboratories rely on single-gene tests. Some laboratories even have to outsource testing for more comprehensive NGS analysis as single-gene tests fail to provide a complete genomic profile of a tumor. Ion Torrent Genexus System is expected to solve many of the problems faced by hospitals when it comes to gene testing thus increasing growth scope for next-generation sequencing.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354

 

Clinical Nutrition Worldwide Market Research Report 2027

 Market scenario:

With the increasing aged population, the clinical nutrition spends are estimated to increase in the future. Due to the weak digestive framework at an old age, it becomes difficult for human body to digest all the required nutrients, rom  food. Among aged population, the loss of appetite is considered a major issue; due to which, the elderly population does not get  necessary amount of nutrients.

Therefore to get sufficient supplements, the confidence of the aged population towards clinical nutrition support, is growing. The global clinical nutrition market is going up because of high birth rate, raise in the number of victims receiving malnutrition treatment, and high number of premature births.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/829 

Key players in the Clinical Nutrition Market:

Abbott (U.S.), AYMES Nutrition International Ltd. (U.K), NeoMed (U.S.), Baxter International (U.S.), Danone (France), B. Braun Melsungen AG (Germany), Mead Johnson & Company, LLC. (U.S.), Nestlé Health Science (Switzerland), Nutricia Advanced  Clinical nutrition (Netherland), Primus Pharmaceuticals (U.S.), Inc., Solace Nutrition (U.K) and others. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population.

Key Developments:

Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players. This help the companies to reach untapped markets in developing nations of the worlds, thus reducing the supply demand gap. The companies develop number of nutritional products for patients, addressing their according to the disease condition. 

Danone:

• Danone is a French multinational food-products company in France. The company introduced, SYNEO which is the first and only hypoallergenic formula containing prebiotics as well as probiotics for the infants suffering from cow’s milk allergy, multiple food allergies, and related gastrointestinal conditions.

Nestlé Health Science:

• In October, 2015, Nestlé Health Science has announced its collaboration with GE Healthcare to improve nutrition monitoring for critically-ill patients. RESOURCE, BOOST, PRONOURISH are some of the major product of the company.
• Nestlé Health Science has acquired Vitaflo headquartered in UK to establish a foothold in the fast-growing market for uniquely formulated products. It has 2nd largest market in US and 1st in Canada.
• In 2015, Nestlé Health Science acquired Phagenesis, a UK-based company developing Phagenyx, an innovative pharyngeal electrical stimulation device to treat dysphagia.
• In July, 2015: Nestlé Health Science signed with Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics) an exclusive agreement outside the United States and Canada for in the fields of Clostridium difficile infections and Inflammatory Bowel Disease (IBD).

Abbott Nutrition:

• Abbott manufactures, and sales enormous clinical nutrition products for adult, infant & new mother, infant & new mother, sports & active living, and therapeutic use. The company supplies these nutrition products under various brand names such as Similac, PediaSure, Pedialyte, Ensure, ZonePerfec, EAS, and Glucerna. The company focuses on healthy diabetes, malnutrition, and heart health.
• June, 2016: Abbott launched new EAS Protein Shakes, Powders and Bars especially for the Athletes with an aim of fuelling their Lifestyles, improving strength, and enhance their performance. The company strives to provide clinically proven nutrition for health-conscious individuals and athletes at every stage of their development, from beginner to professional.
• April, 2016: Abbott Launched EAS Myoplex Sports Nutrition Line for designed for performance. The product form new line are Myoplex Pre-Workout, Myoplex BCAA + Electrolytes, Myoplex Protein Blend, and Myoplex Micellar Casein.

Research in Clinical Nutrition by Key Players:

Abbott:  A research carried out by University of Illinois and Abbott at the Centre for Nutrition, Learning and Memory discovered that children with higher lutein levels in the eye tend to do better on tests of cognition and academic achievement. This help Abbot to understand the role of nutrition on childhood cognition, which will further help the company to develop product providing maximum benefits children enhancing their cognitive abilities.

Therefore, the market is driven by availability of numerous nutritional products, strategic approaches, and geographical expansion by key players. 

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/global-clinical-nutrition-market-829 

Global Surgical Stents Market is Expected to Experience Immense Growth During 2020 – 2023

 Market scenario:

The stent is a small, flexible metal or plastic tube that are inserted into the vessels or duct to keep the passageway open. Different types of materials like metal, standard polymer, and biodegradable polymer are used for the preparation of the surgical stents. According to the WHO (2015), more than 35% of the total global population was suffering from major or minor cardiovascular complications; and in 2014, globally 39% of adults aged 18 years and over were overweight whereas, 13% were obese. Thus, increasing prevalence of diabetes and obesity have increased the risk of urinary tract failure. Major driving factors for the growth of the market: Increasing prevalence of cardiovascular diseases, rising diabetic & obese population and rapid development in the technology. Moreover, rising healthcare expenditure, increasing geriatric population, and changing lifestyle have fueled the growth of the market. However, higher cost of surgeries and risk of infection may hinder the growth of the market during the forecast period 2017-2013.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1044 

Key Players for Global Surgical Stents Market

Some of the major key player for the market are STI Laser Industries, Ltd (Israel), ELLA - CS, s.r.o. (Czech Republic), Boston Scientific Corporation (US), Laserage Technology corporation (US), amg International GmbH (Germany), Abbott (US), Angiocare (Netherlands), Meril Life Sciences Pvt. Ltd. (India), Elixir Medical Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), B. Braun Melsungen AG (Germany), Medtronic (US), Amaranth Medical, Inc (US), Arterial Remodeling Technologies (US).

Segmentation

The global surgical stents market is segmented into types, type of materials, application, and end users. On the basis of types, the global surgical stents market is segmented: cardiac stents, urinary stents, biliary stents, esophageal stents, prostatic stents and other. Cardiac stents are further segmented: self-expanding stents, balloon expanding stents, bio-engineered stents, dual therapy stents, artery stents, drug eluting stents and other. U

Surgical Stents Market to Perceive Momentous Accruals with a hefty CAGR By 2023

rinary stents are further segmented: open end stents, double pigtail stents, closed end stents and multi loop stents. On the basis of materials, the market is segmented: metal, standard polymer, and biodegradable polymer. On the basis of applications, the market is segmented into cardiac diseases, urinary tract diseases, and others. On the basis of end users, the market is segmented into hospital, clinics, and others.

Regional Analysis

America dominates the global surgical stents market owing to an enormous number of the patient suffering from cardiac and renal diseases. Additionally, well-developed healthcare sector and higher healthcare expenditure have supported the growth of the market in this region. Europe accounts for the second largest market followed by Asia Pacific. Asia Pacific is the fastest growing region in the global surgical stents market due to the presence of huge patient population base and rapidly developing economies.

The report for the global surgical stents market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/surgical-stents-market-1044 

Hospital Furniture Market: Information, Analytical Insights and growth of 2020 – 2023

 Market scenario:

Hospital furniture is the most important part of the hospitals. This comprises of all the essential aspects used in the hospital either by physician, staff or patient. Many of the hospitals develop their furniture to attract the patients. The major factors responsible for the growth of global hospital furniture market is increasing number of hospitals and clinics across the globe. Increasing prevalence of different chronic diseases and increasing expectation of the patients toward the hospital infrastructure had also contributed in growth of the market. Continuous development in technology and introduction innovative furniture such as eye surgery chair and advance hospital stretchers has provided fuel for the growth of the market. Whereas, high cost and need of long life furniture has hampered the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1007 

Key players for global hospital furniture market

Stryker Corporation (US), Bio Medical Solutions (India), KI (US), GPC Medical (India), Anetic Aid Limited (UK), DRE INC (US), Bristol Maid Hospital Metalcraft (UK),  The Brewer Company (US), GPC Medical Ltd (India), Chang Gung Medical Technology (China), Hill-Rom (US), Narang Medical (India), Beaver Healthcare Equipment (UK), Renray Healthcare Ltd. (UK), Moore Medical LLC (US), Beaver Healthcare Equipment (UK).

Segmentation

Global hospital furniture market is segmented on the basis of type, into bedside tables, OT table, instrument stands, stretchers, hospital beds, chairs, scrub sinks, waste container, trolley and others. On the basis of application, they are segmented into physician furniture, patient’s furniture and staff’s furniture. Physician furniture is sub segmented into examination table, surgery chair and other. Patient furniture is sub segmented into stretchers, bedside table and other and staff’s furniture is further segmented into stands and other. On the basis of end users, the market is segmented into hospital, diagnostic centres, clinics and others.

Regional analysis

On regional basis, America accounts for the largest market for the global hospital furniture due to high healthcare expenditure and increasing demand for better infrastructure and furniture by people. Europe and Asia Pacific share nearly similar amount of market but Asia Pacific region is expected to grow at the fastest CAGR. The growth of Asia Pacific market is due to presence of rapidly developing economies. Whereas, middle East and Africa has the lowest market for hospital furniture.

The report for global hospital furniture market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/hospital-furniture-market-1007 

Contrast Media Market Poised to Witness a Significant Growth by 2025

 Market Scenario

Contrast Media Market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 4.96 Billion in 2018 and is projected to register a 3.5% CAGR over the forecast period.

Contrast media, also called contrast agents, are chemical components introduced into the body before imaging examination to distinguish normal from abnormal conditions. The companies involved in this market are launching new products and technology with advanced product quality and features. For instance, On November 2019, GE Healthcare receives US Food and Drug Administration (FDA) approval for Clariscan (adulterate meglumine) anionic, gadolinium macrocyclic-based contrast agent injection for intravenous use. Additionally, in September 2019 Bayer AG launched the Medrad Stellant Flex CT injection system that enables contrast dose management.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1284 

The kay factors driving the market growth are the increasing prevalence of cancer, cardiac disease, and also accidental cases, which require medical imaging to examine patient conditions at different stages of treatment increase the demand for global contrast medical market.

However, factors such as side effects, adverse or allergic reactions such as stomach cramps, diarrhea, nausea, vomiting, and constipation hamper the market growth.

Segmentation

The global contrast media market has been segmented into type, form, procedures, application, and route of administration.

The global market, based on type, has been segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barium-based contrast media. On the basis of form, the global contrast media market has been segmented into tablet, powder, liquid, and paste. On the basis of procedures, the market has been segmented into X-ray/computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and others.

Based on application, the market has been segmented into cardiovascular disease, oncology, gastrointestinal disorders, neurological disorders, and other indications.

The global market, by route of administration, has been segmented into rectal, oral, and injectable.

The contrast media market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The contrast media market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European contrast media market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The Asia-Pacific contrast media market has been segmented into Japan, China, India, Latin Korea, Australia, and the rest of Asia-Pacific.

The contrast media market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

DAIICHI (Japan), NANOSCAN IMAGING (US), Bayer AG (Germany), Bracco Diagnostic Inc. (US), GE Healthcare (US), Guerbet Group (France), Jodas Expoim (India), Lantheus Medical Imaging Inc. (US), Magnus Health (US), Spago Nanomedical AB (Germany), and Taejoon Pharm (Korea) are some of the key players in the global contrast media market.

Regional Market Summary

Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global contrast media market owing to the increasing demand for medical imaging, for the diagnosis of various health condition and people suffering from spinal injury, brain problem, intestinal diseases, cancer and other diseases requiring medical imaging. The American Cancer Society, Inc estimated the 1,762,450 people will be diagnosed with cancer in the US in 2019. Such as huge patient population diagnosed with cancer increases the market growth.

Europe is expected to hold the second-largest position in the global contrast media market. The growing economy, increasing healthcare expenditure, and the presence of a large number of medical device companies in this region drive market growth. According to the diagnostic imaging dataset published by The National Health Service (NHS) England it was reported that 41.4 million imaging tests were reported in England from December 2016 to November 2017, in which, plain radiography, that is X-ray, was most common with 1.87 million, followed by diagnostic ultrasonography, ultrasound, computerized axial tomography, and magnetic resonance imaging.

Asia-Pacific is expected to be the fastest-growing region owing to the increasing geriatric population with spinal problems, fractures, and health issues. The increasing patient pool increases the demand for medical imaging, which boosts the contrast media market in this region. 

The Middle East & Africa is estimated to hold the least share of the market. But increasing diagnostic centers, hospitals, and clinics may drive the market growth.

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/contrast-media-market-1284 

PEGylated Drugs Market Ready for a Record-Breaking growth by 2025

 PEGylated Drugs Market is expected to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.

PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to increase the therapeutic efficacy of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings.

The major companies are rigorously investing in R&D of PEGylated drugs and have a good number of molecules in the pipeline. For instance, UCB and Biogen are evaluating the safety and efficacy of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is being developed for the treatment of systemic lupus erythematosus.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8436 

However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period.

Market Dynamics

The Global PEGylated Drugs Market is emerging due to the increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector. For instance, according to the National Cancer Institute, in 2016, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care in the US. This rising prevalence of cancer is creating a demand for effective drugs. The use of advanced drug delivery system with PEGylation technology is significant in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to boost the growth of the global PEGylated drugs market.

Segmentation

The Global PEGylated Drugs Market has been segmented into molecule, indication, and region.

On the basis of molecule, the global PEGylated drugs market has been segmented into protein, enzyme, aptamer, antigen-binding fragment (FAB’ fragment) and others. PEGylated protein is estimated to account for the largest market share of 64.80% during the forecast period. Rising demand for PEGylation, increase in a number of chronic diseases including cancer, and product launches by major market players are propelling the growth of this segment. For instance, in 2018, Coherus Biosciences has gained FDA approval for its Pegfilgrastim biosimilar, Udenyca (Pegfilgrastim-cbqv). Udenyca is a leukocyte growth factor used to decrease the incidence of infection in patients with non-myeloid malignancies.

On the basis of indication, the Global PEGylated Drugs Market has been segregated into cancer, hemophilia, hepatitis, gout, and others.

Regional Analysis

The Global PEGylated Drugs Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas accounted for a market share of 65.73% in 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.

Europe was the second-largest Global PEGylated Drugs Market in 2018. The rising efforts by the government to reduce chronic disease burden owing to the rising occurrence of cancer in the region is projected to drive the market growth. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries has been, segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe.

The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. It holds the third-largest position in the PEGylated drugs market.

The Middle East & Africa is expected to witness a remarkable growth owing to the increasing applications PEGylated drugs for the treatment of chronic diseases.

Prominent Players

The Prominent Players in the Global PEGylated Drugs Market Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG. The players operating in the global PEGylated Drugs Market are focusing on product launches, along with expanding their global footprints by entering untapped markets.    

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/pegylated-drugs-market-8436 

Global Metabolomics Services Market to Significant Growth Foreseen by 2025

 Market Highlights

Metabolomics Services Market is expected to register a CAGR of 7.77%% during the forecast period with a market value of USD 16,291.0 Million till 2025.

 Metabolomics services have been growing at a rapid pace over the last few years. Metabolomics services provide information about the metabolic phenotype by identifying and quantifying the biochemical byproducts of metabolism using different technologically advanced products.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8435

The major key factors driving the market growth are the growing prevalence of diseases such as cancer, neurological disorders, and cardiac diseases across the globe, technological advancements in instrumentation, and increasing application of metabolomics in the life science and biotechnological industry. However, factors such as high cost of instruments and stringent government policies/regulations may hamper the market growth. 

Segment Analysis

The Global Metabolomics Services Market is segmented into product and service and application. Based on product and service, the market has been segmented into chromatography, metabolomics bioinformatics services, and mass spectrometry. On the basis of application, the global metabolomics services market has been segmented into biomedical and pharmaceutical, agriculture, and food.

Regional Analysis

The Global Metabolomics Services Market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas are expected to hold the largest share of the global metabolomics services market. This is owing to the increasing patient population suffering from cancer, and cardiovascular diseases are boosting the market growth in this region.

The Europe market holds the second-largest position in the global metabolomics services market due to the presence of a large number of companies such as Biocrates Life Sciences AG (Biocrates), Bruker, Waters, and other providing metabolomics services drives the growth of the market in this region.

Asia-Pacific is estimated to be the fastest-growing region owing to a large number of patient population suffering from chronic disease and increasing demand for treatment for the same.  

The metabolomics services market in the Middle East & Africa accounts for the least market share due to the adequate healthcare infrastructure support accounted for a relatively smaller market share in 2018.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Metabolomics Services Market—Agilent Technologies, Inc. (US), Waters (US), Bruker (US), TMIC (CANADA), Thermo Fisher Scientific (US), Biocrates Life Sciences AG (AUSTRIA), Creative Proteomics (US), Human Metabolome Technologies America Inc (JAPAN), Shimazdu Corporation (Japan), and Metabolon, INC (US)

Key Findings of the Study

• The Global Metabolomics Services Market was valued at USD 9,729.0 million in 2018, is estimated to grow at USD 16,291.0 Million by 2025 at a CAGR of 7.77%% during the assessment period

• America accounted for the largest share of the global market due to the presence of a huge patient population suffering from chronic diseases.

• Based on application, the biomedical and pharmaceutical segment accounted for the largest market share in 2018

 

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/metabolomics-services-market-8435